| Umsatz in Mio. | - |
| Operatives Ergebnis (EBIT) in Mio. | -689,52 $ |
| Jahresüberschuss in Mio. | -600,09 $ |
| Umsatz je Aktie | - |
| Gewinn je Aktie | -3,58 $ |
| Gewinnrendite | -26,49% |
| Umsatzrendite | - |
| Return on Investment | -23,46% |
| Marktkapitalisierung in Mio. | 7.337 $ |
| KGV (Kurs/Gewinn) | -12,22 |
| KBV (Kurs/Buchwert) | 3,24 |
| KUV (Kurs/Umsatz) | - |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | +88,54% |
| Geld/Brief | 67,00 € / 68,50 € |
| Spread | +2,24% |
| Schluss Vortag | 67,50 € |
| Gehandelte Stücke | 357 |
| Tagesvolumen Vortag | 26.882,5 € |
| Tagestief 68,00 € Tageshoch 68,50 € | |
| 52W-Tief 27,00 € 52W-Hoch 69,50 € | |
| Jahrestief 27,00 € Jahreshoch 69,50 € | |
| 31.12.2025 | Quartalsmitteilung |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 66,00 € | 0 % | 66,00 € | 09:31 | |
| Frankfurt | 67,00 € | +1,52% | 66,00 € | 08:02 | |
| Hamburg | 67,00 € | +0,75% | 66,50 € | 08:12 | |
| München | 67,00 € | +1,52% | 66,00 € | 08:00 | |
| Stuttgart | 66,50 € | +2,31% | 65,00 € | 07:33 | |
| L&S RT | 67,75 € | +0,74% | 67,25 € | 12:29 | |
| Berlin | 67,50 € | +0,75% | 67,00 € | 12:12 | |
| NYSE | 78,435 $ | +0,98% | 77,675 $ | 04.12.25 | |
| Nasdaq | 78,48 $ | +1,02% | 77,69 $ | 04.12.25 | |
| AMEX | 78,52 $ | +1,08% | 77,68 $ | 04.12.25 | |
| Tradegate | 68,50 € | +1,48% | 67,50 € | 11:20 | |
| Quotrix | 67,50 € | +0,75% | 67,00 € | 07:27 | |
| Gettex | 67,00 € | -1,47% | 68,00 € | 12:13 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 04.12.25 | 67,50 | 26.883 |
| 03.12.25 | 67,00 | 59 T |
| 02.12.25 | 65,00 | 8.765 |
| 01.12.25 | 65,50 | 43.696 |
| 28.11.25 | 67,00 | 62 T |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 67,00 € | +1,49% |
| 1 Monat | 52,00 € | +30,77% |
| 6 Monate | 35,20 € | +93,18% |
| 1 Jahr | 44,60 € | +52,47% |
| 5 Jahre | 33,40 € | +103,59% |
| Marktkapitalisierung | 9,81 Mrd. € |
| Aktienanzahl | 168,22 Mio. |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +8,43% | Vanguard Group Inc |
| +7,66% | Farallon Capital Management, L.L.C. |
| +5,67% | HHG PLC |
| +5,49% | Wellington Management Company LLP |
| +5,01% | Baker Bros Advisors LP |
| +4,63% | BlackRock Inc |
| +4,45% | FMR Inc |
| +4,07% | Nextech Invest, Ltd. |
| +3,26% | Paradigm Biocapital Advisors LP |
| +2,67% | Bvf Inc |
| +2,52% | State Street Corp |
| +2,52% | T. Rowe Price Associates, Inc. |
| +2,51% | T. Rowe Price Investment Management,Inc. |
| +2,45% | Bellevue Group AG |
| +2,21% | Alphabet Inc |
| +1,94% | Holocene Advisors, LP |
| +1,81% | Deerfield Management Co |
| +1,60% | Geode Capital Management, LLC |
| +1,56% | Woodline Partners LP |
| +1,54% | Casdin Capital, LLC |
| +27,99% | Weitere |
| 0,00% | Streubesitz |
Zahlen für Q2/23
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-reports-second-quarter-2023-financial
Übernahme von EQRx
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-inc-acquire-eqrx-inc-all-stock-transaction
300 Mio. $ Offering
https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-pricing-3000-million-public